Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist - United States
doi 10.1634/theoncologist.2016-0229
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Feasibility Study of Personalized Peptide Vaccination for Metastatic Recurrent Triple-Negative Breast Cancer Patients

Breast Cancer Research
Cancer ResearchOncology
2014English

Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer

Clinical Cancer Reviews
2009English

Phase II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

The Internet Journal of Oncology
2007English

A Phase 2 and Biomarker Study of Cabozantinib in Patients With Advanced Cholangiocarcinoma

Cancer
Cancer ResearchOncology
2017English

Immediate and Long-Term Outcomes of Drug Treatment in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2018English

PIM-1 Kinase: A Potential Biomarker of Triple-Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy